"The U.S. Food and Drug Administration today approved the Intercept Blood System for plasma, the first pathogen reduction system for use by blood establishments in the preparation of plasma in order to reduce the risk of transfusion-transmitted in"...
In general, Lamprene (clofazimine) is well tolerated when administered in dosages no greater than 100 mg daily. The most consistent adverse reactions are usually dose related and are usually reversible when Lamprene (clofazimine) is discontinued.
Adverse Reactions Occurring In More Than 1% of Patients
Adverse Reactions Occurring In Less Than 1% of Patients
Skin:Phototoxicity, erythroderma, acneiform eruptions, monilial cheilosis.
Ocular: Diminished vision.
Psychiatric:Depression secondary to skin discoloration; two suicides have been reported.
Read the Lamprene (clofazimine) Side Effects Center for a complete guide to possible side effects
Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene (clofazimine) have not been confirmed. If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.
Read the Lamprene Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 11/5/2008
Additional Lamprene Information
- Lamprene Drug Interactions Center: clofazimine oral
- Lamprene Side Effects Center
- Lamprene FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
Find out what women really need.